JT002 is an orally active NLRP3 inflammasome inhibitor that reduces the production of NLRP3-dependent pro-inflammatory cytokines (e.g., IL-1β, IL-1α, IL-18) and pyroptosis; it blocks the formation of the NLRP3 inflammasome complex and attenuates airway hyperresponsiveness and airway neutrophilia in mice.